Tirzepatide and its links to heart health and death rates in people with obesity and diabetes

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Fernando Gerchman reports a relationship with Eli Lilly and Company that includes: consulting or advisory and speaking and lecture fees. Fernando Gerchman reports a relationship with Merck & Co Inc that includes: consulting or advisory and speaking and lecture fees. Fernando Gerchman reports a relationship with Novo Nordisk that includes: speaking and lecture fees. Fernando Gerchman reports a relationship with Abbott Laboratories that includes: speaking and lecture fees. All other authors report no competing interests.